Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMSC in Reducing Hemodialysis Arteriovenous Fistula Failure
NCT02808208Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2017
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in vascular access complication (5 arms), sponsored by Mayo Clinic. Primary endpoint: Hemodialysis outflow vein diameter at 12 months. Started Jun 2017; status: active, not recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
vascular access complication
Beyond the preview
Go deeper on NCT02808208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808208.